Pneumotox Online
v2.2
  • RSS Feed
  • Contact
  • News
  • Diagnosing DIRD
  • Browse
  • Available on AppStore Available on AppStore

The Drug-Induced Respiratory Disease Website

Philippe Camus, M.D.

Dijon, France

  • Home
  • Browse by »
  • Drugs
  • Patterns

Pembrolizumab

5

XIX.a BAL: An excess proportion of lymphocytes

1
Last update : 07/03/2018
 
Search
Advanced search
Identify causative drugs
Diagnosing DIRD
1
Drug and radiation history
2
Drug singularity - Correct identification of the drug
3
Consistent timing of exposure v. onset of symptoms
4
Clinical, imaging, BAL, pathological pattern consistent with the specific drug
5
Careful exlusion of another cause
6
Remission of symptoms with removal of drug
7
Recurrence with rechallenge (rarely advisable)
8
Causality assessment
More detailed checklist
See also under
Atezolizumab
2
Immune checkpoint inhibitors (ICI) - ICI combinatorial Rx
5
Ipilimumab
4
Lambrolizumab
4
Nivolumab
5
PD-1/PD-L1-inhibitors or blocking agents/drugs
5

Publications

A "Crazy Paving" Pattern on CT Scan in a Patient Treated with Pembrolizumab.
Current drug safety 2019;14;242-245 2019
Surface marker profiles on lung lymphocytes may predict the mechanism of immune-mediated pneumonitis triggered by tumor-infiltrating lymphocytes in lung cancer patients treated with pembrolizumab.
Lung cancer (Amsterdam, Netherlands) 2018 Apr;118;171-172 2018 Apr
Pembrolizumab-induced pneumonitis.
ERJ open research 2017 Apr;3; 2017 Apr
A Case of Organizing Pneumonia (OP) Associated with Pembrolizumab.
Drug target insights 2016;10;9-12 2016

Powered by

  • ^
  • Contact
  • Cookies
  • About

The Pneumotox website uses cookies. By accessing or using our website, you consent to the collection, use and disclosure of the garnered information in accordance with our privacy policy.

Learn more about cookies